With the introduction of tyrosine kinase inhibitors (TKI), patients with chronic myeloid leukemia (CML) have obtained survival rates close to normal. It may appear paradoxical, then, that medication adherence is suboptimal in some health care settings. As the first of its kind, this study aimed to explore drivers and barriers to TKI treatment adherence in Danish CML patients. A literature study informed the design of qualitative interviews with 20 patients, individually and in focus groups, focusing on their disease perceptions of CML, their health-related quality of life (QoL) and medication adherence. The study showed that many participants had previously switched treatment due to lacking efficacy or intolerance but most felt their current disease burden was tolerable. Anxiety might, however, resurface if treatment stopped working or with the occurrence of infections or side effects, creating a state of 'fragile peace'. To these patients, their role functioning -as professionals, spouses, parents and grandparents -was crucial to uphold a positive self-image and meaningful life. Whether treatment enabled or hindered this was thus decisive to their QoL and medication adherence. Our participants expressed high adherence rates with only one having intentionally non-adhered due to side effects and poor QoL. Most participants felt well-informed about CML and treatment and privileged to receive specialised personal care from the public health care system acting to motivate their medication adherence. As a novel finding, this study indicates that the prospect of treatment-free remission may positively affect adherence. We suggest this should be explored in future studies.
Introduction
Chronic myeloid leukaemia (CML) constitutes approximately 15% of adult leukaemia cases. It affects slightly more men than women and has an average onset at 64-68 years. Most patients (60-85%) are diagnosed in the initial chronic phase (CP-CML) based on symptoms such as night sweats, abdominal pain, infections, fatigue, weight loss, or bruising [1] [2] [3] .
15-40% are asymptomatic and often identified by routine blood tests. If untreated, CP-CML will progress to an accelerated phase (AP-CML) and a fatal blast phase (BP-CML) in three to five years [1, 4, 5] .
With the introduction of the tyrosine kinase inhibitor (TKI) imatinib in 2001, CML patients have obtained revolutionary survival rates close to normal [6] .
2
nd generation TKIs dasatinib, nilotinib, and bosutinib have since been approved [7] , followed by 3 rd generation ponatinib [4, 8, 9] . Some patients are initially treated with hydroxyurea [4] . Prior to TKIs, patients could be treated with interferon-alpha (IFNa), and allogeneic stem-cell transplantation (SCT) remains an option with elevated mortality rates. As CML is a lowgrade symptom disease, treatment often represents patients' main disease impact [3, 10] . Side effects are mostly considered mild to moderate but may include edema, diarrhoea, pleural effusions, nausea, muscosceletal or abdominal pain, rashes, fatigue, or headache [1] [2] [3] [4] 7, 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
Three levels of TKI treatment response may be obtained: complete hematologic, cytogenetic, and molecular responses (CHR, CCyR, and CMR) reflecting successive decrease in leukemic cells [4] . Efficacy is highest in CP-CML and certain milestone responses should occur within 3, 6, and 12 months after initiating treatment [4, 22] . Treatment should be re-evaluated if milestones are not reached [23, 24] . Response rates are deeper and faster with 2 nd generation TKIs compared to imatinib, and patients with rapid response have better long-term outcomes than those with slower or no response to therapy [11, 13, 17, 20, 22 ]. Yet imatinib is still the most widely used TKI due to cost-effectiveness and acceptable side effects. CML patients with long-lasting sustained CMR, amounting to 10-15% of patients, may be eligible for discontinuation [9, 12, 16, 18, 25] .
Medication adherence, i.e. 'the extent of conformity to the recommendations about day to day treatment by the provider with respect to timing, dosage and frequency' [3] is crucial to achieve optimal treatment response [6] [7] [8] 11, 12, 17, [26] [27] [28] [29] [30] [31] 32 ]. Yet the fact that CML has become a manageable chronic disease with much improved quality of life (QoL) may challenge adherence [4, 8, 26] . Non-adherence in up to 25-30% of CML patients have been suggested [4, 7, 19, [26] [27] [28] 30, 33] . Side effects are the most frequent reason for intentional non-adherence and has been associated with a negative impact on activities such as travels, other illness, psycho-social well-being and QoL [3, 4, 6, 7, [9] [10] [11] [13] [14] [15] 17, 26, 29, 31, 33, 34] .
Unintentional non-adherence is mostly due to careless slips. Non-adherence has also been linked to lacking knowledge about CML and treatment, co-payment, poor communication from health care providers and complacency due to sustained disease control [2] [3] [4] 6, 7, [10] [11] [12] 14, 17, 19, [26] [27] [28] [29] [30] [31] [32] [35] [36] [37] [38] [39] . Results diverge about adherence and type of TKI and may relate to the drug as well as patients' experiences with earlier treatments [7, 8, 19] .
The aim with the present study was to explore in depth the drivers and barriers to CML patients' adherence in a Danish health care setting.
Materials and methods
We used qualitative methods in order to examine patient perspectives on factors that may affect adherence behaviour in Danish CML patients. An initial literature search was carried out in PubMed, Embase and PsycInfo using the search terms 'chronic myelogenous/myeloid/myelocytic leukemia/CML' or 'chronic granulocytic leukemia/CGL' in combination with 'patient' and 'perspectives/experiences/ preferences' or 'quality of life' or 'adherence/compliance/nonadherence'.
From a total of 341 identified abstracts of journal articles published within the past ten years, 67 described QoL and treatment adherence in patients with CML and were thus selected for full-text analysis -five used qualitative methods [19, 29, 35, 37, 38] .
The literature study informed the research design using focus groups to elicit discussions about a The focus groups lasted two hours and were moderated by G. Lee Mortensen using a semi-structured interview guide [40, 41] . When introducing the focus group discussions, the participants were told of the aim Table 1 ).
The interviews were transcribed verbatim and analysed using Nvivo 8 software (QSR International) and inductive content analysis [42] . This involved an analysis of the participants' statements in a manner to generate clusters of meaning about their perceptions of CML and treatment. First, the transcripts were read through numerous times (by two researchers independently) to get familiar with the data. Secondly, the data was coded into topics (categories) that were raised during the focus groups -mostly reflecting the topics in the question guide -and discussed among the researchers until agreement was reached. Some categories were collapsed; others were spilt up into separate categories.
Thirdly, the main themes (sub-categories) within each topic were identified, and finally, recurrent connections between topics and themes were analysed. This generated a pattern of the relative significance that the topics and themes had for the participants, i.e. their perceptions of CML and drivers and barriers to treatment adherence.
Results
The 20 participants were aged between 36-75 years (mean 60.9) and had been diagnosed for [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] years (mean 6.23). 18 had a partner, all had children (four living at home) and 13 were grandparents. At the time of the interviews, they attended haematological clinics at seven hospitals across Denmark, 12 were retired, four worked reduced hours and five still had fulltime work. Previously, six had worked reduced hours and six had taken early retirement due to the diagnosis (Table 2) . 
Opening question
• First names and time of CML diagnosis
Quality of life (QoL) impact of CML
• Reactions to the CML diagnosis • QoL impacts -whatever is important to your life and daily well-being (ensuring the following are covered):
• parenting, and working were described as particularly important to sustaining meaning, identity and normality.
The participants described that, today, the main impact In CML, adherence has been measured using various methods, e.g. as percentage rates, using adherence measure scores, or categorising adherence into low, medium or high levels [31] . Previous studies These factors are all known drivers to adherence along with longer disease duration, fear of the consequences of not adhering, using concurrent medication, having social support and using systems of reminders. Our results also confirm previous study results that relate higher levels of adherence to higher perceived functional status and QOL, including ability to work, and low burden of symptoms and side effects [3, 6, 7, 11, 12, 14, 26, [28] [29] [30] [31] 33, 35, 38] . Our participants described their role functioning as crucial to uphold a positive self-image and normality, which they felt was vital to a meaningful life. Symptoms thus became especially burdensome when negative affecting identity and social relations.
Only one participant had intentionally nonadhered to TKI treatment and few had considered it.
Our study confirms that side effects were a main reason for this, exacerbated by comorbidity and poor social support. Side effects thus acted as a barrier to adherence due to its reduction in his psychosocial well-being and role functioning [3, 6, 9, 14, 33, 38] . Several participants suggested that comprehensive patient care should include psychosocial support including information about peer support from patient networks.
Though very rare, careless slips were the most common reason for unintentional non-adherence in our participants. Unlike other studies, our sample did not a l l o w u s t o a s s o c i a t e t h i s w i t h y o u n g e r a g e , l i v i n g a l o n e a n d m a l e g e n d e r , h o w e v e r [2] [3] [4] 6, 7, 10, 11, 14, 17, 19, 26, [28] [29] [30] [31] [37] [38] [39] . While others have suggested that non-adherence may be caused by complacency and sustained disease control [4, 6, [29] [30] [31] 38] , this was not the case in our participants although some speculated this might be the case in settings without public health care. Paradoxically then,
higher QoL -stemming from successful treatment -may thus act as a barrier as well as a driver to adherence.
Only few studies have assessed patient perspectives on planned medication discontinuation due to sustained treatment response. Sanford and colleagues
showed that side effects and daily adherence were reasons for some patients to want and feel safe discontinuing, while fear of relapse and disappointing others were reasons to reject discontinuation [16] . In another study, half the patients dared not discontinue even if their treatment response was optimal, but 16%
were interested to avoid side effects, and 20% were indifferent [12] . In our explorative study, the participation of four patients in treatment-free remission 
